A Free Service Provided By



Legal Topics

Arbitration and Mediation
Car Accidents
Child Support
Child Custody & Visitation

Copyright Law
Criminal Law
Dangerous Drugs
DUI Drunk Driving

Elderly Laws
Employees' Rights
Estate Planning
Family Law
Immigration Law

Lemon Law
Medical Malpractice
Megan's Law
Mesothelioma & Asbestos

Probate & Estates
Product Recalls
Real Estate

Statute of Limitations

Taxes & the IRS
Traffic Violations
Workers' Compensation
Work Related Injury

Privacy Policy

Contact Us

About Us

Facts - Books - News    U.S. Facts Of Law:

Vioxx, FDA Health Advisory - Sept 30, 2004

On September 30, 2004, and FDA Health Advisory was issued announcing that Merck was announcing a voluntary withdrawal of Vioxx from the market due to safety concerns.  Vioxx was a commonly prescribed drug in the non-steroidal anti-inflammatory drug (NSAID) family.  It was approved by the FDA in 1999 for the management of pain and inflammation and was widely prescribed to arthritis sufferers.

A long term study of Vioxx on patients suffering from recurrent colon polyps was stopped early in September 2004 for safety reasons.  Subjects of the study using Vioxx showed an increased risk of heart attack and stroke compared to subjects taking a placebo.  Merck voluntarily pulled Vioxx from the market on September 30th.


Vioxx FDA Health Advisory Best Sellers from

(no title)


Newsfeed display by CaRP

Vioxx FDA Health Advisory News
GN News

This RSS Feed URL Is Deprecated
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at

Celebrex As Safe As Ibuprofen And Naproxen, FDA Advisers Say NPR
NPR Celebrex As Safe As Ibuprofen And Naproxen, FDA Advisers Say NPR Food and Drug Administration advisers found that celecoxib poses no greater risk for heart attacks and strokes than prescription doses of popular pain relievers and more raquo

Shocker Is Vioxx Coming Back As An Orphan Drug MedPage Today Blog
MedPage Today blog Shocker Is Vioxx Coming Back as an Orphan Drug MedPage Today blog Don39t forget that Celebrex is available as a generic, and last week, an FDA Advisory Committee concluded its cardiovascular risks are no greater than those of naproxen or ibuprofen. I want to hear from you. We know that our incentive system is a

FDA Advisors Weigh COX2 Inhibitor Safety MedPage Today
MedPage Today FDA Advisors Weigh COX 2 Inhibitor Safety MedPage Today Deliberations on Tuesday by a joint FDA advisory committee centered largely on the randomized PRECISION trial, with discussion wading deep into the trial39s details, but with little substantial objections or concern voiced over its findings or conduct.

Lillyaposs Baricitinib Wins FDA Panel Nod, But Still Dogged By Safety Issues ...
Lilly39s baricitinib wins FDA panel nod, but still dogged by safety issues BioPharma Dive While the FDA normally follows suit with advisory committee votes, the unresolved data issues surrounding baricitinib could spur an unusual departure, or at the very least a restricted label. quotAny panel discussion that includes comparisons to Vioxx and more raquo

IMPORTANT NOTICE: This webpage is Copyrighted content.  No portion of this page may be copied to any other webpage, forum, blog or other domain page or offline publication without written permission from Violators will be prosecuted to the fullest extent of the law.

The information provided by does not constitute legal advice or any other type of advice and is provided for educational purposes only without warranty of any kind. has not reviewed the information on this page for accuracy and is not responsible for any errors, omissions or inaccuracies.  For legal advice you should consult a licensed attorney.


Copyright All Rights Reserved -
No Portion of This Page May Be Copied Without Written Permission

Facts of Law about the vioxx fda health advisory

Facts of Law - Vioxx FDA Health Advisory